{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.3956","value":"1120.759"},{"groupId":"OG001","spread":"22.1528","value":"1267.523"},{"groupId":"OG002","spread":"71.9314","value":"1020.344"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Pevonedistat 20 mg/m\\^2, infusion, IV, once, on Day 1 of Part A in participants with normal renal and hepatic function with hematologic malignancies (MDS and AML).","id":"OG000","title":"Part A: Control Arm: Pevonedistat 20 mg/m^2"},{"description":"Pevonedistat 20 mg/m\\^2, infusion, IV, once, on Day 1 of Part A in participants with severe renal impairment with hematologic malignancies (MDS and AML).","id":"OG001","title":"Part A: Renal Arm: Pevonedistat 20 mg/m^2"},{"description":"Pevonedistat 20 mg/m\\^2, infusion, IV, once, on Day 1 of Part A in participants with mild hepatic impairment with hematologic malignancies (MDS and AML).","id":"OG002","title":"Part A: Mild Hepatic Arm: Pevonedistat 20 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population included all participants who had sufficient dosing in Part A and Part B Cycle 1, had sufficient concentration-time data to permit reliable estimation of PK parameters, and who had not received any excluded concomitant medications through the completion of Part A.","reportingStatus":"POSTED","timeFrame":"Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose","title":"Part A, AUClast: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration for Pevonedistat Following a Single Dose","type":"PRIMARY","unitOfMeasure":"h*ng/mL"}